Vnitr Lek 2017, 63(4):272-276 | DOI: 10.36290/vnl.2017.055

How to create cooperative patient for antihypertensive and hypolipidemic therapy

Jan Piťha1,2
1 Interní klinika 2. LF UK a FN Motol, Praha
2 Centrum experimentální medicíny IKEM, Praha

Patient drug adherence is a major problem especially in the prevention of cardiovascular disease of atherosclerotic origin. On one hand, antihypertensive drugs and hypolipidemic drugs/statins are among the most successful, ones the other hand, they are among the drugs which are most frequently skipped by the patients. Improvement could be realized by education of patients, more frequent follow-ups, as well as by the use of new technologies involving specific dispensers and other, even more sophisticated methods. Nevertheless, among the most successful strategies is the simplification of medication, particularly the use of drugs with a longer half-life and the use of combination of several drugs in a single tablet. Therefore, we have quite wide range of options to improve patient compliance. However, some disadvantages should be kept in mind associated with these techniques. The aim of this article is to discuss potential problems and solutions associated with patient adherence/compliance with respect to antihypertensive and hypolipidemic treatment with an emphasis on practical approach.

Keywords: drug adherence; dyslipidemia; hypertension; pharmacotherapy

Received: April 3, 2017; Accepted: April 27, 2017; Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Piťha J. How to create cooperative patient for antihypertensive and hypolipidemic therapy. Vnitr Lek. 2017;63(4):272-276. doi: 10.36290/vnl.2017.055.
Download citation

References

  1. ADHERENCE TO LONG-TERM THERAPIES. Evidence for action. World Health Organization: 2003. ISBN 92 4 154599 2. Dostupné z WWW: <http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf>.
  2. Epstein RS. Medication adherence: hope for improvement? Mayo Clin Proc 2011; 86(4): 268-270. <http://dx.doi.org/10.4065/mcp.2011.0123>. Go to original source... Go to PubMed...
  3. Zdravotnická ročenka České republiky. Dostupné z WWW:<http://www.uzis.cz/katalog/rocenky/zdravotnicka-rocenka-ceske-republiky>.
  4. Chytil L, Strauch B, Cvačka J et al. Determination of doxazosin and verapamil in human serum by fast LC-MS/MS: application to document non-compliance of patients. Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(30): 3167-3173. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jchromb.2010.09.032>. Go to original source... Go to PubMed...
  5. Strauch B, Petrák O, Zelinka T et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013; 31(12): 2455-2461. Go to original source... Go to PubMed...
  6. Ceral J, Habrdova V, Vorisek V et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res 2011; 34(1): 87-90. Go to original source... Go to PubMed...
  7. Kallem RR, Karthik A, Chakradhar L et al. Development and validation of a highly sensitive and robust LC-MS/MS with electrospray ionization method for quantification of rosuvastatin in small volume human plasma samples and its application to a clinical study. Arzneimittelforschung 2007; 57(11): 705-711. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031-1296671>. Go to original source... Go to PubMed...
  8. Waldron J, Webster C. Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins. Ann Clin Biochem 2011; 48(Pt 3): 223-232. Dostupné z DOI: <http://dx.doi.org/10.1258/acb.2010.010182>. Go to original source... Go to PubMed...
  9. Bramlage P, Sims H, Minguet J et al. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk. Eur J Prev Cardiol 2017; 24(3): 297-310. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487316674817>. Go to original source... Go to PubMed...
  10. Papageorgiou N, Zacharia E, Briasoulis A et al. Statins and myocardial infarction: Type, dose, and administration time: Does it matter? Trends Cardiovasc Med 2016; 26(5): 433-441. <http://dx.doi.org/10.1016/j.tcm.2016.01.001>. Go to original source... Go to PubMed...
  11. Elis A, Lishner M. Non-every day statin administration-a literature review. Eur J Intern Med 2012; 23(5): 474-478. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2012.02.006>. Go to original source... Go to PubMed...
  12. Marcus FI, Baumgarten AJ, Fritz WL et al. Alternate-day dosing with statins. Am J Med 2013; 126(2): 99-104. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2012.08.007>. Go to original source... Go to PubMed...
  13. Kim YS, Sunwoo S, Lee HR et al. Korea Post-Marketing Surveillance Research Group. Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients. Pharmacoepidemiol Drug Saf 2002; 11(7): 593-600. Go to original source... Go to PubMed...
  14. Projekt intenzivního ovlivnění dyslipidémií u pacientů s ischemickou chorobou dolních končetin. Practicus 2016; 10: 9-11. Dostupné z DOI: <http://dx.doi.org/http://web.practicus.eu/sites/cz/Documents/Practicus-2016-10/09-ICHDK.pdf>.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.